Corporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...

Indian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...

Global markets are under pressure due to rising bond yields and geopolitical tensions. Higher crude oil prices are a key concern, potential...

Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...

Cipla shares: Following the earnings announcement, several brokerage firms revised their target price for the stock, with some estimates re...

Meanwhile, EBITDA for the quarter under review increased 13% YoY to Rs 1,316 crore as against 1166 crore in the last year period.

On the India business front, in particular, Cipla is working to not only enhance its prescription base but also strengthen its trade generi...

Actor was founded in 2009 and has quickly grown to become the fifth largest privately owned OTC player in the South African market. Actor s...

Cipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 81586.39 Crore) operating in Pharmaceuticals s...

Cipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 73903.56 Crore) operating in Pharmaceuticals s...

Analysts expect Cipla to report a consolidated net profit of Rs 616.8 crore on net sales of Rs 5,003 crore, according to estimates from six...

Three leading pharma companies announced their June quarter results towards the end of the week — each with different levels of performance...

Cipla beat expectations riding the demand for Covid medication. The Street is likely to push the stock to its record high hit in 2015. Whil...

Shares of drug major Cipla today gained over 6 per cent after the company reported 17.47 per cent increase in net profit for the July-Septe...

The stock of pharma major Cipla has mostly underperformed the ET pharma index in 2010 due to its lacklustre financial performance.

Cipla’s latest move to grow through acquisitions comes at a time when the company has been growing at lower than the industry growth rate f...

In its results update on pharmaceutical major Cipla, brokerage KR Choksey has advised investors to Hold the stock for a price target of Rs ...